Vesicoureteral Reflux (VUR)

1. Clinical Overview

Summary

Vesicoureteral Reflux (VUR) is the retrograde flow of urine from the bladder into the ureter and kidney, representing a failure of the normal one-way valve mechanism at the vesicoureteral junction (VUJ). It is the most common urological abnormality in children, found in approximately 30-40% of children investigated following febrile urinary tract infection (UTI). [1,2]

VUR arises from either primary (congenital) abnormalities of the vesicoureteral junction or secondary causes such as increased bladder pressure from posterior urethral valves or neuropathic bladder. The fundamental concern is the "Big Equation": VUR + UTI = Pyelonephritis → Renal Scarring → Reflux Nephropathy → Hypertension / Chronic Kidney Disease (CKD). [3,4]

The condition exhibits a strong familial tendency with autosomal dominant inheritance and incomplete penetrance. Diagnosis is confirmed by Micturating Cystourethrogram (MCUG), which also provides grading (I-V) essential for prognostication and management planning. Renal scarring is detected by DMSA scan (technetium-99m dimercaptosuccinic acid scintigraphy). [5,6]

Management has evolved significantly over the past two decades. The traditional approach of routine antibiotic prophylaxis for all grades of VUR has been challenged by landmark trials (RIVUR, PRIVENT, Swedish Reflux Trial), leading to a more nuanced, individualized strategy. Current management ranges from conservative surveillance (most low-grade VUR resolves spontaneously by age 5-7 years) to minimally invasive endoscopic injection (Deflux) or open/laparoscopic ureteric reimplantation (Cohen, Leadbetter-Politano techniques) for high-grade reflux or breakthrough infections with progressive renal damage. [7,8,9]

Clinical Pearls

VUR is Common After Febrile UTI: Up to 30-40% of children with febrile UTI have VUR. Investigation protocols vary by age and UTI characteristics (atypical, recurrent) according to NICE CG54 guidelines.

Most Low-Grade VUR Resolves Spontaneously: Grade I-III VUR resolves in 70-90% of cases by age 5-7 years with bladder maturation and lengthening of the intramural ureter. Resolution rates decline with increasing grade.

Infection + Reflux = Scarring: Sterile reflux alone rarely causes renal damage. The combination of bacteriuria with reflux of infected urine into the renal pelvis and parenchyma drives pyelonephritis and subsequent scarring.

DMSA Scan Shows Scarring, Ultrasound Does Not: Renal ultrasound has poor sensitivity (30-40%) for detecting cortical scarring. DMSA scintigraphy is the gold standard with 85-95% sensitivity for identifying areas of reduced uptake corresponding to scarred segments.

Familial Screening is Indicated: Siblings of children with VUR have a 30-50% risk of VUR themselves, particularly those under 2 years. Non-invasive screening with renal ultrasound and consideration of VCUG in high-risk siblings is recommended.

The Antibiotic Prophylaxis Debate: RIVUR trial (2014) showed prophylaxis reduced recurrent UTI by 50% but did not significantly reduce renal scarring. Contemporary practice individualizes prophylaxis based on VUR grade, bladder-bowel dysfunction, and family preference.

---

2. Epidemiology

Incidence and Prevalence

Exam Detail: MRCPCH Exam Point: Be prepared to quote the 30-40% prevalence in children with febrile UTI and 30-50% sibling risk. These are high-yield statistics for MCQs and viva stations on investigating UTI in children.

The prevalence demonstrates an inverse relationship with age: highest in infancy (particularly less than 1 year) and declines with increasing age, reflecting both spontaneous resolution and the age-dependent improvement in vesicoureteral junction competence.

Demographics

Sex Distribution:

• Overall: Female predominance (approximately 65-70%) due to higher UTI rates in females leading to more frequent detection
• Infants less than 1 year: Male predominance (approximately 60-70%), often detected through investigation of antenatally diagnosed hydronephrosis or early-onset febrile UTI
• After age 1 year: Female predominance becomes established and increases with age [12]

Age at Presentation:

• Peak diagnosis: 1-3 years, coinciding with peak UTI incidence
• Antenatal detection: Increasing identification through prenatal ultrasound detecting hydronephrosis
• Late diagnosis: Occasionally diagnosed in adolescence or adulthood during investigation of hypertension, proteinuria, or reflux nephropathy

Ethnicity:

• Caucasian children: Higher prevalence (approximately 1.5-2x) compared to African-American children
• Risk of scarring: May vary by ethnicity independent of VUR grade, though data are conflicting [13]

Socioeconomic Factors:

• No strong association with socioeconomic status
• Access to healthcare and early treatment of UTI may influence scarring outcomes

Familial Clustering

VUR demonstrates strong familial aggregation consistent with autosomal dominant inheritance with incomplete penetrance (estimated 60-70% penetrance). [10]

Genetic Considerations:

• Sibling recurrence risk: 30-50% (much higher than population baseline)
• Offspring of affected parents: 25-40% risk
• Candidate genes: Multiple loci identified including PAX2, ROBO2, BMP4, though most cases are polygenic
• Gender influence: Female offspring of affected males may have higher risk and severity

Clinical Implication: Screening of siblings, particularly those under 2 years of age, is recommended. Strategies include:

1. Non-invasive: Renal ultrasound surveillance with low threshold for VCUG if UTI occurs
2. Invasive: Direct VCUG screening in siblings less than 2 years (controversial due to radiation exposure)

---

3. Aetiology and Pathophysiology

Normal Vesicoureteral Junction Anatomy

The vesicoureteral junction (VUJ) functions as a passive one-way valve preventing retrograde flow of urine from bladder to ureter during bladder filling and micturition. [14]

Anatomical Components:

1. Oblique Ureteral Entry: The ureter enters the bladder wall at an oblique angle (not perpendicular)
2. Intramural Tunnel: The ureter passes through the bladder wall (detrusor muscle) for 1.5-2.5 cm before opening at the ureteric orifice
3. Submucosal Tunnel: The terminal ureter runs submucosally for several millimeters before the orifice
4. Length-to-Diameter Ratio: Optimal anti-reflux mechanism requires tunnel length:ureteral diameter ratio of 5:1

Mechanism of Valve Competence:

• During bladder filling, intravesical pressure increases
• The intramural ureter is compressed passively between bladder mucosa and underlying detrusor muscle
• This compression occludes the ureteral lumen, preventing reflux
• The longer the intramural tunnel, the more effective the valve mechanism

Waldeyer's Sheath: The terminal ureter is surrounded by longitudinal smooth muscle (Waldeyer's sheath) which continues into the bladder trigone. Contraction may help actively close the ureteral orifice during voiding.

Primary VUR: Congenital VUJ Abnormality

Primary VUR accounts for approximately 80-85% of cases and results from developmental defects of the vesicoureteral junction.

Anatomical Defects in Primary VUR:

1. Short Intramural Tunnel: Most common defect. The ureter enters the bladder at a more perpendicular angle with insufficient submucosal tunnel length.
2. Lateral Ureteric Orifice Position: The orifice is displaced laterally on the trigone rather than at the normal posteromedial position. Lateral orifices have shorter tunnels.
3. Patulous Orifice: A "golf-hole" appearance indicating weak muscular support around the orifice.
4. Absent or Deficient Waldeyer's Sheath: Reduced longitudinal muscle support.

Embryological Basis:

• The ureteric bud arises from the mesonephric (Wolffian) duct
• Abnormal origin of the ureteric bud (too cranial or caudal) leads to abnormal incorporation into the bladder, resulting in ectopic or laterally positioned orifices with inadequate tunnel length
• Multiple genetic pathways regulate ureteric budding, bladder development, and VUJ formation

Natural History - Spontaneous Resolution: With bladder growth and maturation:

• The bladder base increases in size
• The intramural tunnel lengthens passively
• The tunnel-to-diameter ratio improves, restoring valve competence
• Resolution is age-dependent and grade-dependent

Resolution Rates by Grade (based on pooled data): [15]

• Grade I: 80-85% resolve by age 5 years
• Grade II: 75-80% resolve by age 5 years
• Grade III: 50-60% resolve by age 7-8 years
• Grade IV: 30-40% resolve (may take up to 10 years)
• Grade V: Less than 10% resolve; surgical correction usually required

Exam Detail: Pathophysiology Viva Question: "Why does VUR improve with age?"

Model Answer: "VUR improves with age due to passive lengthening of the intramural ureteral tunnel as the bladder grows. The normal anti-reflux mechanism depends on a tunnel length-to-ureteral diameter ratio of approximately 5:1. In primary VUR, the intramural tunnel is congenitally short. As the child grows, the bladder base expands, and the intramural portion of the ureter lengthens proportionally. This increases the length-to-diameter ratio, improving the passive valve mechanism. This explains why low-grade VUR (grades I-III) has high spontaneous resolution rates (70-90% by age 5-7 years), while high-grade VUR with more severe anatomical defects has lower resolution rates. Additionally, bladder maturation improves bladder compliance and reduces dysfunctional voiding, which can reduce reflux severity."

Secondary VUR: Acquired Causes

Secondary VUR results from elevated intravesical pressure overwhelming an otherwise competent VUJ, or from bladder pathology disrupting the VUJ mechanism. It accounts for 15-20% of VUR cases.

Causes of Secondary VUR:

Prognosis of Secondary VUR: Secondary VUR has a lower spontaneous resolution rate than primary VUR because the underlying abnormality (e.g., neuropathic bladder, PUV) persists. Management must address the underlying cause. For example, VUR may persist even after PUV ablation if bladder dysfunction remains.

The Pathogenesis of Renal Scarring: VUR + Infection = Damage

The critical concept is that VUR alone (sterile reflux) rarely causes significant renal damage. Scarring occurs when infected urine refluxes into the kidney, causing acute pyelonephritis followed by inflammatory fibrosis. [3,4]

The Scarring Cascade:

1. Bacterial Ascent: E. coli (80-90% of UTIs) or other uropathogens colonize the bladder.
2. Reflux of Infected Urine: During voiding, infected urine refluxes up the ureter into the renal pelvis and calyces.
3. Intrarenal Reflux (IRR): In susceptible papillae (particularly polar "compound" papillae with concave morphology), infected urine refluxes directly into collecting ducts and renal parenchyma.
4. Pyelonephritis: Bacterial invasion of renal parenchyma triggers acute inflammation (neutrophils, cytokines, tissue injury).
5. Acute Renal Injury: Tubular necrosis, interstitial edema, vascular congestion.
6. Healing with Fibrosis: Inflammatory resolution leads to fibrosis, tubular atrophy, and cortical thinning (scarring).
7. Chronic Consequences: Focal scarring → Reduced nephron mass → Compensatory hyperfiltration in remaining nephrons → Glomerular hypertension → Proteinuria → Progressive CKD. Renin secretion from ischemic scarred segments → Hypertension.

Intrarenal Reflux (IRR) is the key mechanism linking VUR to scarring:

• Compound papillae (located at renal poles) have concave, gaping orifices that allow reflux into collecting ducts
• Simple papillae (mid-kidney) have slit-like orifices resistant to IRR
• This explains why polar scarring (upper and lower poles) is the classic pattern in reflux nephropathy [16]

Age Vulnerability - The "Critical Window":

• Infants and young children (less than 2-3 years) are most susceptible to renal scarring
• Possible mechanisms:
  • Higher prevalence of compound papillae allowing IRR
  • Immature immune response to bacterial infection
  • Delayed diagnosis due to non-specific symptoms
• After age 4-5 years, new scar formation is rare even with VUR and UTI (though existing scars can worsen)
• This concept underpins the urgency of early UTI diagnosis and treatment in young children [4]

Exam Detail: Viva Question: "Why does vesicoureteral reflux cause renal scarring?"

Model Answer: "Renal scarring in VUR results from the combination of reflux and infection, not from reflux alone. When infected urine refluxes from the bladder into the kidney during voiding, bacteria are delivered directly to the renal pelvis. In susceptible areas - particularly the renal poles where compound papillae have concave orifices - infected urine can reflux into the collecting ducts themselves, a process called intrarenal reflux. This leads to acute pyelonephritis with bacterial invasion of the parenchyma, triggering an intense inflammatory response. The subsequent healing process results in fibrosis, tubular atrophy, and cortical thinning - i.e., scarring.

The key point is that sterile reflux rarely causes damage. Studies of children with VUR but no UTI show minimal scarring. Conversely, the combination of VUR and recurrent UTI, particularly in infants and young children under 3 years of age, carries the highest risk of progressive renal damage. This is why prevention and prompt treatment of UTI is the cornerstone of VUR management, and why the benefit of antibiotic prophylaxis - which reduces UTI but not necessarily scarring - remains debated."

---

4. Classification: International Reflux Grading System

The International Reflux Study Classification (1981, revised 1985) grades VUR from I to V based on the extent of retrograde urine flow and the degree of ureteral and pelvicalyceal dilation as visualized on micturating cystourethrography (MCUG/VCUG). [17]

Grading is critical because it correlates with:

• Spontaneous resolution rates (higher grades resolve less often)
• Risk of renal scarring (higher grades carry greater risk)
• Management strategy (low-grade: conservative; high-grade: surgical consideration)

VUR Grading Table

Exam Detail: MCQ High-Yield Point: The transition from Grade II to Grade III is defined by the presence of mild-to-moderate dilation with blunting of fornices. Grade II has reflux into the collecting system but no dilation. This distinction frequently appears in exam questions showing MCUG images.

Viva Scenario: You may be shown an MCUG image and asked to grade the VUR. Systematic approach:

1. Does contrast reach the ureter? (If no → No VUR. If yes → Continue)
2. Does contrast reach the renal pelvis? (If no → Grade I)
3. Is there dilation of the ureter, pelvis, or calyces? (If no → Grade II)
4. If dilated, assess severity:
   • Mild-moderate dilation, minimal fornix blunting → Grade III
   • Moderate dilation, significant fornix blunting, tortuosity → Grade IV
   • Gross dilation, complete loss of detail, massively tortuous → Grade V

Bilateral vs. Unilateral VUR

• Unilateral VUR: 50-60% of cases. Better prognosis. Contralateral kidney provides functional reserve.
• Bilateral VUR: 40-50% of cases. Higher risk of CKD if both kidneys scar. Grades may differ between sides (e.g., left grade II, right grade IV).

Clinical Implication: Bilateral high-grade VUR is a red flag requiring aggressive management due to risk of bilateral renal damage and CKD.

---

5. Clinical Presentation

Typical Presentations

VUR is asymptomatic until complications occur. It typically presents in one of the following ways:

1. Febrile Urinary Tract Infection (Most Common)

Presentation:

• Fever (often high-grade, greater than 38.5°C) without obvious source
• Irritability, lethargy (especially in infants and young children)
• Vomiting, poor feeding, failure to thrive (infants)
• Abdominal or loin pain (older children)
• Dysuria, frequency, urgency (if associated cystitis)

Key Point: In young children (less than 2-3 years), pyelonephritis may present with fever and non-specific symptoms only, without localizing urinary signs. VUR is found in 30-40% of children investigated after first febrile UTI. [1,2]

Investigation Triggers (NICE CG54): [18]

• Infants less than 6 months with any UTI → USS + consider DMSA + MCUG
• Children 6 months to 3 years with atypical or recurrent UTI → USS + DMSA ± MCUG
• Atypical UTI features: Seriously unwell, poor urine flow, abdominal/bladder mass, raised creatinine, failure to respond to antibiotics within 48 hours, non-E. coli organism

2. Antenatal Hydronephrosis

Presentation:

• Prenatal diagnosis: Hydronephrosis detected on antenatal ultrasound (usually second or third trimester)
• Postnatal follow-up: Renal ultrasound confirms persistent hydronephrosis
• Postnatal MCUG: Performed to distinguish VUR from obstructive causes (UPJ obstruction, PUV)

Prevalence: VUR is found in 15-25% of cases of antenatal hydronephrosis (lower than historically thought; many cases are transient or physiological). [11]

Clinical Strategy:

• Postnatal USS at 48 hours to 1 week (earlier USS may underestimate severity due to neonatal dehydration)
• If persistent hydronephrosis (especially bilateral, or hydroureter present) → MCUG to exclude VUR or PUV
• Antibiotic prophylaxis while awaiting investigations in high-risk cases

3. Recurrent Urinary Tract Infections

Definition: Two or more episodes of pyelonephritis, or one pyelonephritis plus one cystitis, or three or more cystitis episodes.

Presentation: Pattern of repeated febrile illnesses or symptomatic UTIs in a young child.

Investigation: MCUG indicated to identify VUR as an underlying predisposing factor. DMSA scan performed 4-6 months after acute infection to assess for scarring.

4. Incidental Finding on Family Screening

Presentation: Asymptomatic child, sibling of known VUR patient, undergoes screening ultrasound showing hydronephrosis or subsequently MCUG confirming VUR.

Rationale: 30-50% sibling risk justifies screening, particularly in children less than 2 years. Strategy debated due to radiation exposure from MCUG and uncertain benefit of detecting asymptomatic VUR.

5. Late Presentation: Reflux Nephropathy

Presentation (Adolescent or Adult):

• Hypertension (detected on routine screening)
• Proteinuria (detected on urinalysis)
• Chronic Kidney Disease (elevated creatinine, reduced eGFR)
• Renal imaging shows small, scarred kidneys (unilateral or bilateral)

Diagnosis: Reflux nephropathy diagnosed retrospectively. History may reveal recurrent childhood UTIs. VUR may have resolved by this stage, but damage persists.

Significance: VUR is a leading cause of end-stage renal disease (ESRD) in children and young adults, accounting for 5-15% of paediatric CKD cases. [4]

Clinical Pearl: "The Silent Destroyer": Some children with VUR have asymptomatic UTIs (bacteriuria without overt symptoms) and are diagnosed only when renal scarring has already occurred. This underscores the importance of maintaining a high index of suspicion for UTI in young children with unexplained fever, and the value of sibling screening in high-risk families.

---

6. Examination Findings

General Inspection

In most cases, examination is entirely normal between UTI episodes. VUR itself has no specific physical signs.

During Acute UTI/Pyelonephritis:

• Fever: Often high-grade (greater than 38.5°C)
• Unwell appearance: Irritability, lethargy, toxic appearance
• Dehydration signs: If vomiting, poor fluid intake

Growth Parameters:

• Failure to Thrive: Chronic UTIs or advanced renal impairment may cause poor weight gain
• Plot on growth chart: Any crossing of centiles should prompt investigation

Abdominal Examination

Inspection:

• Scars from previous surgery (ureteric reimplantation, PUV ablation)

Palpation:

• Normal in most cases
• Palpable kidney: Rarely, a grossly hydronephrotic kidney (high-grade VUR, Grade IV-V) may be palpable as a smooth, ballotable mass in the flank or upper abdomen
• Suprapubic tenderness: May indicate cystitis during acute UTI
• Loin tenderness: May indicate pyelonephritis during acute UTI

Percussion:

• Renal angle tenderness (loin percussion tenderness) may be present in acute pyelonephritis (less reliable in young children)

Cardiovascular Examination

Blood Pressure Measurement (Essential):

• Use age-appropriate cuff (bladder width covering 40% of arm circumference; length covering 80-100%)
• Compare to centile charts for age, sex, and height
• Hypertension is a key complication of reflux nephropathy
• May be detected even in childhood if significant bilateral scarring
• Suspect reflux nephropathy if hypertension in a child with history of recurrent UTI

Significance: Hypertension due to reflux nephropathy results from activation of the renin-angiotensin-aldosterone system (RAAS) by ischemic scarred renal segments. Long-term sequelae include left ventricular hypertrophy and cardiovascular morbidity.

Genitourinary Examination

External Genitalia:

• Labial adhesions (females): May contribute to recurrent UTI
• Meatal stenosis (males): Rare cause of bladder outlet obstruction → secondary VUR
• Hypospadias, epispadias: Rarely associated with VUR
• Posterior urethral valves (males): Not visible externally, but consider if bilateral hydronephrosis and poor urinary stream

Urinary Stream Observation:

• If possible (or from parental history), assess for poor stream or dribbling (suggests bladder outlet obstruction)

Spinal Examination

Lumbosacral Spine (Essential in Neuropathic Bladder Suspected):

Examine the back for stigmata of occult spinal dysraphism (tethered cord, spina bifida occulta):

• Midline sacral dimple (especially if greater than 2.5 cm from anus, or deep/atypical)
• Tuft of hair (hypertrichosis)
• Lipoma or mass over spine
• Capillary hemangioma (port-wine stain)
• Asymmetric gluteal cleft

Neurological Examination of Lower Limbs:

• Assess tone, power, reflexes, sensation in lower limbs
• Absent ankle jerks or foot deformities may suggest sacral nerve involvement

Clinical Significance: Neuropathic bladder due to spinal dysraphism causes secondary VUR with high bladder pressures. This carries a worse prognosis with higher risk of renal damage. Early neurosurgical intervention (e.g., detethering) and urological management (clean intermittent catheterization, anticholinergics) are essential.

---

7. Differential Diagnosis

VUR must be distinguished from other causes of hydronephrosis, recurrent UTI, and renal scarring in children.

Differential Diagnosis Table

Exam Detail: Viva Question: "How do you differentiate VUR from UPJ obstruction on imaging?"

Model Answer:

"The key difference is the ureter:

• UPJ obstruction: Dilated renal pelvis and calyces, but the ureter is normal or minimally dilated. The obstruction is at the pelviureteric junction, so urine cannot exit the renal pelvis, but the ureter distal to this is unaffected.
• VUR: If high-grade (III-V), you see hydroureter (dilated ureter) along with hydronephrosis. The dilation extends down the full length of the ureter.

Additionally:

• MCUG: Definitive. UPJ obstruction shows no reflux. VUR shows retrograde filling of ureter and collecting system during voiding.
• MAG3 Renogram: In UPJ obstruction, shows obstructive curve (T1/2 greater than 20 minutes) with delayed drainage even after furosemide. In VUR, drainage is typically normal unless very high-grade.

Finally, clinical context helps: UPJ obstruction is often an isolated antenatal finding with less association with UTI, whereas VUR commonly presents with recurrent febrile UTI."

---

8. Investigations

Imaging Pathway After UTI (Based on NICE CG54)

Investigation strategy is age-stratified and UTI-type-stratified (typical vs. atypical vs. recurrent). [18]

Definitions:

• Atypical UTI: Seriously ill, poor urine flow, abdominal/bladder mass, raised creatinine, failure to respond to appropriate antibiotics within 48 hours, infection with non-E. coli organism
• Recurrent UTI: Two or more episodes of UTI with pyelonephritis, or one episode of pyelonephritis plus one or more episodes of cystitis, or three or more episodes of cystitis

NICE Guideline Summary (CG54)

Rationale:

• Infants less than 6 months: Highest risk group for VUR and renal damage. Lower threshold for invasive imaging.
• Older children: VUR less likely to cause new scarring after age 4-5 years. Reserve MCUG for selected cases.

Key Investigations

1. Renal and Bladder Ultrasound (USS KUB)

Purpose:

• First-line imaging in all children with atypical or recurrent UTI
• Detects structural abnormalities: hydronephrosis, hydroureter, duplex kidney, bladder abnormalities
• Assesses kidney size and echogenicity (scarring appears as increased echogenicity and reduced size)

Findings in VUR:

• Often normal in low-grade VUR (I-II)
• Hydronephrosis and/or hydroureter in high-grade VUR (IV-V)
• Small, echogenic kidney: Suggests chronic scarring/reflux nephropathy
• Duplex kidney: Associated with VUR in lower moiety

Limitations:

• Cannot diagnose VUR (functional, not anatomical, at low grades)
• Poor sensitivity for renal scarring (30-40% sensitivity vs. 85-95% for DMSA)

Timing:

• During acute illness (atypical UTI) or within 6 weeks (recurrent UTI)

2. Micturating Cystourethrogram (MCUG) / Voiding Cystourethrogram (VCUG)

Purpose:

• Gold standard for diagnosing and grading VUR
• Assesses bladder anatomy and urethra (detects PUV in males)

Technique:

• Urinary catheterization (transurethral)
• Bladder filled with radio-opaque contrast (diluted) via catheter using gravity feed
• Fluoroscopic imaging during filling phase and voiding phase (catheter removed for voiding)
• Reflux is graded (I-V) based on extent and severity of retrograde flow

Findings:

• VUR: Retrograde filling of ureter/pelvis during voiding (or sometimes during filling in severe cases)
• Bladder: Trabeculation (suggests chronic high pressure), diverticula
• Urethra (males): Posterior urethral valves (dilated posterior urethra, filling defect), urethral stricture

Limitations and Considerations:

• Invasive: Catheterization uncomfortable and small risk of introducing infection (antibiotic prophylaxis often given)
• Radiation exposure: Gonadal radiation (though dose minimized with modern technique)
• Intermittent reflux: Some VUR is intermittent and may not be detected on a single study
• Cyclic VCUG: Some centers perform multiple fill-void cycles to increase sensitivity

Indications (from NICE CG54):

• All infants less than 6 months with UTI (typical, atypical, or recurrent)
• Atypical or recurrent UTI in infants/children 6 months to 3 years (especially if abnormal USS, non-E. coli, family history)
• Abnormal antenatal USS (hydronephrosis, particularly if bilateral or hydroureter present)
• Sibling screening (controversial; some centers perform, others use USS surveillance only)

Alternative: Radionuclide Cystography (RNC):

• Uses technetium-99m pertechnetate instead of contrast
• Lower radiation dose (50-100 times less than MCUG)
• Cannot visualize urethra (so cannot detect PUV)
• Useful for follow-up to assess resolution, or for sibling screening (particularly females where PUV not a concern)

3. DMSA Scan (Technetium-99m Dimercaptosuccinic Acid Scintigraphy)

Purpose:

• Gold standard for detecting renal scarring (reflux nephropathy)
• Assesses differential renal function (split function: left vs. right kidney contribution)

Technique:

• IV injection of Tc-99m DMSA (binds to proximal tubular cells)
• Gamma camera imaging after 2-4 hours (allows renal uptake and background clearance)
• Images show renal outlines with uptake intensity reflecting functioning renal parenchyma

Findings:

• Normal: Smooth, uniform renal outlines with symmetric uptake (split function 45-55% each kidney)
• Acute pyelonephritis: Areas of reduced uptake (photopenic defects) that are reversible (repeat DMSA after 4-6 months shows resolution)
• Renal scarring: Permanent areas of reduced/absent uptake with overlying cortical thinning and distortion. Classic pattern: polar scarring (upper and lower poles)
• Differential function: Quantifies each kidney's contribution (e.g., left 35%, right 65% suggests left kidney scarring/damage)

Timing:

• Acute DMSA (during or within 1 week of acute UTI): Detects pyelonephritis (transient defects)
• Late DMSA (4-6 months post-UTI): Detects permanent scarring. Recommended timing per NICE guideline.

Clinical Significance:

• Scarring on DMSA indicates that renal damage has occurred, changing prognosis and management
• Children with scarring require:
  • Long-term follow-up (BP, renal function, proteinuria)
  • More aggressive VUR management (consider intervention)
  • "Counseling re: hypertension and CKD risk"

Limitations:

• Radiation exposure (though low dose)
• Cannot differentiate old vs. new scars (need serial scans)
• Reduced uptake may also be seen in dysplastic kidney, chronic pyelonephritis from other causes

Exam Detail: MCQ Stem: "A 2-year-old girl presents with her third episode of febrile UTI. Renal ultrasound shows mild left-sided hydronephrosis. MCUG confirms Grade III left VUR. DMSA scan performed 5 months after her most recent UTI shows reduced uptake in the left upper and lower poles. What does this finding represent?"

Answer: Permanent renal scarring (reflux nephropathy). DMSA performed 4-6 months post-infection distinguishes permanent scarring (persistent defects) from acute pyelonephritis (which resolves). The polar distribution is classic for VUR-associated scarring due to intrarenal reflux at compound papillae.

4. MAG3 Renogram (Technetium-99m Mercaptoacetyltriglycine Renography)

Purpose:

• Assesses renal drainage and differential function
• Used primarily to diagnose obstruction (UPJ, UVJ) rather than VUR

Technique:

• IV injection of Tc-99m MAG3 (secreted by proximal tubules, excreted in urine)
• Dynamic imaging over 20-30 minutes shows uptake, transit, and drainage phases
• Furosemide (Lasix) given at 15-20 minutes to augment drainage ("F+15" or "F+20" protocol)

Findings:

• Normal: Rapid uptake, peak at 3-5 minutes, washout after furosemide (T1/2 less than 10 minutes)
• Obstruction (UPJ/UVJ): Delayed drainage, T1/2 greater than 20 minutes post-furosemide
• VUR: Usually shows normal drainage unless very high-grade

Use in VUR:

• Not primary investigation
• May be performed if coexistent hydronephrosis on USS and MCUG shows VUR, to exclude additional obstruction
• In high-grade VUR with massive dilation, MAG3 can help assess whether poor drainage is due to reflux alone or superimposed obstruction requiring intervention

5. Urodynamic Studies

Purpose:

• Assess bladder function: capacity, compliance, detrusor pressure, voiding dynamics
• Identify neuropathic bladder, detrusor-sphincter dyssynergia, bladder outlet obstruction

Technique:

• Catheterization with pressure transducers
• Bladder filled while measuring intravesical pressure, detrusor pressure (Pdet = Pves - Pabd)
• Voiding phase with pressure-flow studies and EMG of pelvic floor

Findings in Secondary VUR:

• High detrusor pressures (greater than 40 cmH2O) during filling or voiding → risk of upper tract damage
• Detrusor overactivity, poor compliance, detrusor-sphincter dyssynergia

Indications:

• Suspected neuropathic bladder (spinal dysraphism, tethered cord)
• Posterior urethral valves (post-ablation to assess bladder function)
• Dysfunctional voiding unresponsive to behavioral measures

Clinical Relevance:

• High bladder pressures require intervention (CIC, anticholinergics) to protect upper tracts, even if VUR is corrected surgically

6. Urine Dipstick and Culture

Purpose:

• Diagnose UTI
• Guide antibiotic therapy (culture and sensitivities)
• Surveillance for asymptomatic bacteriuria

Technique:

• Clean catch urine (older children)
• Urine bag (unreliable due to contamination; only negative result useful)
• Catheter sample or suprapubic aspirate (SPA) (gold standard in infants; less contamination)

Interpretation:

• Dipstick: Nitrites (high specificity for UTI), leukocyte esterase (sensitive but less specific)
• Microscopy: Pyuria (white cells), bacteriuria
• Culture: Significant bacteriuria defined as greater than 10^5 colony-forming units/mL (clean catch) or any growth (SPA)

Follow-Up Cultures:

• During antibiotic prophylaxis: Regular monitoring (e.g., monthly) for breakthrough UTI
• Post-treatment: Ensure clearance of infection

7. Renal Function Tests

Blood Tests:

• Urea and Creatinine: Baseline renal function. Elevated if significant bilateral scarring/CKD.
• eGFR (estimated glomerular filtration rate): Calculated from creatinine using pediatric formulas (Schwartz equation). Normal eGFR greater than 90 mL/min/1.73m².
• Electrolytes: May show hyperkalemia, metabolic acidosis in advanced CKD.

Urine Tests:

• Urinalysis for proteinuria: Protein:creatinine ratio (PCR). Significant proteinuria (PCR greater than 50 mg/mmol) indicates glomerular damage.
• Microalbuminuria: Early marker of renal damage.

Indications:

• Baseline in all children with VUR
• Monitoring in children with scarring, bilateral high-grade VUR, or known reflux nephropathy

---

9. Management

Management of VUR has undergone a paradigm shift over the past two decades, moving from routine surgical correction to a more individualized, conservative-first approach informed by landmark trials. [7,8,9]

Management Principles

Goals:

1. Prevent febrile UTI (and thus prevent new renal scarring)
2. Facilitate spontaneous resolution of VUR with bladder maturation
3. Monitor for complications (breakthrough UTI, new scarring, hypertension, CKD)
4. Intervene surgically when conservative measures fail or high-grade VUR unlikely to resolve

Factors Influencing Management:

• VUR Grade: Lower grades (I-III) managed conservatively; higher grades (IV-V) often require intervention
• Age: Younger children have higher resolution rates; older children with persistent VUR less likely to resolve
• Bilateral vs. Unilateral: Bilateral high-grade carries higher risk
• Presence of Renal Scarring: Existing scarring or new scarring on follow-up DMSA increases urgency for intervention
• Breakthrough UTI: Recurrent UTI despite prophylaxis may prompt surgical intervention
• Bladder-Bowel Dysfunction (BBD): Presence of BBD reduces resolution rates and must be treated
• Family Preferences: Compliance with prophylaxis, tolerance of risk of recurrent UTI vs. surgical intervention

Management Algorithm

CHILD WITH VUR (Diagnosed on MCUG)
           ↓
ASSESS SEVERITY AND RISK FACTORS
- VUR Grade (I-V)
- Unilateral vs. Bilateral
- Renal Scarring (DMSA)
- Age
- Bladder-Bowel Dysfunction
           ↓
┌──────────────────────────────────────────┐
│                                          │
LOW-MODERATE GRADE (I-III)           HIGH GRADE (IV-V)
No/Minimal Scarring                  OR Bilateral III-IV
Age less than 5-7 years              OR Significant Scarring
│                                          │
CONSERVATIVE MANAGEMENT              INITIAL TRIAL CONSERVATIVE
│                                    (if age less than 2 years)
- Antibiotic Prophylaxis             OR
  (Trimethoprim 1-2 mg/kg nocte      SURGICAL INTERVENTION
   OR Nitrofurantoin 1 mg/kg nocte)  │
  [Individualized decision]          │
- Treat Bladder-Bowel Dysfunction    │
  (Constipation treatment, timed     │
   voiding, biofeedback)             │
- Avoid Holding/Infrequent Voiding   │
- Education re: Prompt UTI Diagnosis │
- Surveillance Imaging               │
  * USS every 6-12 months            │
  * DMSA at 1-2 years                │
  * Repeat MCUG at 1-2 years (if     │
    considering stopping prophylaxis)│
- Monitor BP, Urinalysis             │
│                                    │
REASSESS AT 1-2 YEARS                │
           ↓                         │
VUR RESOLVED OR DOWNGRADED           │
→ STOP PROPHYLAXIS                   │
→ CONTINUE SURVEILLANCE              │
           ↓                         │
VUR PERSISTENT BUT STABLE            │
→ CONTINUE CONSERVATIVE              │
→ REASSESS AT INTERVALS              │
           ↓                         │
BREAKTHROUGH UTI                     │
OR NEW/WORSENING SCARRING ───────────┤
OR PERSISTENT HIGH-GRADE VUR         │
AFTER AGE 5-7 YEARS                  │
           ↓                         │
     INTERVENTION                    │
           ↓                         │
 ┌─────────┴──────────┐              │
 │                    │              │
ENDOSCOPIC        OPEN/LAPAROSCOPIC  │
INJECTION         URETERIC           │
(Deflux/STING)    REIMPLANTATION     │
 │                    │              │
 └────────┬───────────┘              │
          ↓                          │
  POST-OPERATIVE FOLLOW-UP           │
  - USS (check hydronephrosis)       │
  - VCUG at 3-6 months (confirm      │
    resolution)                      │
  - Long-term BP/Renal Function      │
    Monitoring                       │

Conservative Management

1. Antibiotic Prophylaxis: The Evidence Debate

Rationale: Low-dose, once-daily antibiotics aim to prevent bacteriuria, thereby preventing febrile UTI and subsequent renal scarring.

Common Regimens:

• Trimethoprim: 1-2 mg/kg once daily (at night)
• Nitrofurantoin: 1 mg/kg once daily (at night) [Avoid in infants less than 3 months; contraindicated if eGFR less than 30]
• Cephalexin: 10 mg/kg once daily (alternative if resistance)

Duration: Continued until VUR resolves (confirmed on repeat VCUG) or child reaches age 5-7 years (low risk of new scarring thereafter).

Landmark Trials and Meta-Analyses:

1. RIVUR Trial (NEJM 2014) [7]:

   • Design: RCT, 607 children (age 2-71 months) with Grade I-IV VUR after first or second febrile UTI
   • Intervention: Trimethoprim-sulfamethoxazole prophylaxis vs. placebo for 2 years
   • Results:
     • Recurrent UTI: 13.9% (prophylaxis) vs. 26.0% (placebo) — 50% relative risk reduction (P less than 0.001)
     • Renal scarring on DMSA: No significant difference between groups (8.2% vs. 7.2%, P=0.55)
   • Conclusion: Prophylaxis reduced UTI recurrence but did not reduce renal scarring. Benefit must be weighed against antibiotic exposure, resistance, and adverse effects.

2. PRIVENT Trial (Lancet 2009): [8]

   • Design: RCT, 576 children with VUR or recurrent UTI
   • Intervention: Trimethoprim prophylaxis vs. no prophylaxis
   • Results: No significant reduction in UTI recurrence or renal scarring
   • Criticism: Mixed population (included non-VUR recurrent UTI), lower power

3. Swedish Reflux Trial (J Urol 2010): [9]

   • Design: RCT comparing surveillance, antibiotic prophylaxis, and endoscopic injection in infants with Grade III-IV VUR
   • Results: Prophylaxis reduced febrile UTI vs. surveillance. Endoscopic injection (Deflux) reduced VUR but similar UTI rates (lower power).

4. Cochrane Review (2011, Updated 2019):

   • Meta-analysis of RCTs: Antibiotic prophylaxis reduces risk of repeat symptomatic UTI (RR 0.68) but no clear benefit on renal scarring
   • Heterogeneity in studies limits conclusions

Current Consensus (American Urological Association, European Association of Urology, NICE):

• Antibiotic prophylaxis is not universally mandatory for all VUR
• Individualized decision based on:
  • "Grade III-V VUR: Prophylaxis often recommended (higher UTI risk)"
  • "Grade I-II VUR: Prophylaxis optional (lower risk; many clinicians use surveillance alone)"
  • "Bladder-bowel dysfunction: Treat BBD first; may reduce UTI without antibiotics"
  • "Recurrent breakthrough UTI: Prophylaxis has failed; consider intervention"
  • "Family preference: Discussion of benefits (UTI reduction) vs. risks (resistance, adverse effects, compliance burden)"

Adverse Effects and Concerns:

• Antimicrobial resistance: Long-term prophylaxis may select for resistant organisms (E. coli resistance to trimethoprim up to 30-40% in some cohorts)
• Adverse drug reactions: Rash, GI upset (rare with low dose)
• Compliance: Daily medication for years; adherence variable

Exam Detail: Viva Question: "What is the evidence for antibiotic prophylaxis in VUR?"

Model Answer:

"The role of antibiotic prophylaxis in VUR has been extensively studied, most notably in the RIVUR trial published in the New England Journal of Medicine in 2014. This randomized controlled trial of over 600 children with Grade I-IV VUR showed that trimethoprim-sulfamethoxazole prophylaxis reduced the rate of recurrent febrile UTI by approximately 50% compared to placebo - from 26% down to 14% over 2 years. However, crucially, there was no significant reduction in renal scarring on DMSA scanning between the two groups.

This finding has shifted practice away from universal prophylaxis toward a more individualized approach. Current guidelines from the AUA and EAU suggest that:

• Prophylaxis may be considered for higher-grade VUR (III-V) where UTI risk is greater
• For lower-grade VUR (I-II), surveillance without prophylaxis is often appropriate
• The decision should involve shared decision-making with families, weighing the benefit of UTI reduction against concerns about antibiotic resistance, side effects, and compliance

Other important trials include the PRIVENT trial and Swedish Reflux Trial, with somewhat conflicting results, and Cochrane meta-analyses showing modest UTI reduction but no clear scarring benefit. The key take-home message is that prophylaxis reduces infection but not necessarily the long-term renal outcome we care most about - scarring - and therefore is not mandatory in all cases."

2. Bladder-Bowel Dysfunction (BBD) Management

Importance: BBD (constipation, infrequent voiding, holding, urgency, enuresis) is present in 30-50% of children with VUR and significantly reduces spontaneous resolution rates and increases UTI risk. [19]

Assessment:

• Voiding diary (frequency, volume)
• Bowel history (Bristol stool chart, frequency, withholding, soiling)
• Validated questionnaires (Dysfunctional Voiding Symptom Score - DVSS)

Interventions:

• Constipation treatment: Laxatives (Movicol/macrogol, lactulose), dietary fiber, fluid intake
• Timed voiding: Regular, scheduled voiding (every 2-3 hours) to prevent bladder overdistension
• Pelvic floor biofeedback: Teaching relaxation during voiding (reduces detrusor-sphincter dyssynergia)
• Avoid "holding": Encourage complete, unhurried voiding in relaxed setting
• Treat urgency/overactivity: Anticholinergics (oxybutynin, tolterodine) if urodynamically proven detrusor overactivity

Evidence: Studies show that successful BBD treatment improves VUR resolution rates and reduces UTI, independent of antibiotic prophylaxis.

3. Surveillance Imaging

Objectives: Monitor for VUR resolution, detect new scarring, assess renal growth and function.

Recommended Schedule (varies by institution):

• Renal USS: Every 6-12 months (assess renal size, growth, hydronephrosis)
• DMSA scan: At 1-2 years post-diagnosis, or sooner if breakthrough UTI (assess for new scarring)
• Repeat VCUG: At 12-24 months, or when considering stopping prophylaxis (assess for resolution or downgrading)
• Blood pressure: Every visit (at least annually)
• Urinalysis: Every visit (proteinuria screen)
• Renal function (U&E): Annually if bilateral VUR or scarring

Decision to Stop Prophylaxis:

• Repeat VCUG showing resolution or downgrading to Grade I
• Age greater than 5-7 years (low risk of new scarring even if VUR persists)
• Shared decision-making if Grade II-III persists but stable

4. Parental Education and UTI Awareness

Key Messages:

• Recognize symptoms of UTI (fever without obvious source, irritability, vomiting, dysuria)
• Seek early medical attention (prompt diagnosis and treatment prevents scarring)
• Compliance with prophylaxis (if prescribed)
• Hygiene measures (front-to-back wiping in girls, adequate fluid intake, regular voiding)
• Avoid constipation (link between constipation and UTI)

Surgical Management

Surgical intervention is considered when:

1. High-grade VUR (IV-V) unlikely to resolve spontaneously
2. Breakthrough febrile UTI despite prophylaxis
3. New or worsening renal scarring on serial DMSA scans
4. Persistent VUR beyond age 7-8 years with ongoing UTI risk
5. Non-compliance with prophylaxis or follow-up
6. Parental preference for definitive treatment over long-term antibiotics

Two main surgical approaches: Endoscopic injection and open/laparoscopic ureteric reimplantation.

1. Endoscopic Subureteric Injection (STING / Deflux)

Technique:

• Cystoscopy under general anesthesia
• Injection of a bulking agent (dextranomer/hyaluronic acid copolymer — trade name "Deflux") into the submucosal space just beneath the ureteric orifice
• Creates a "nipple" or mound that narrows the orifice and lengthens the functional intramural tunnel, improving valve competence
• STING technique (Subureteric Transurethral Injection): Needle inserted just below orifice at 6 o'clock position

Bulking Agents:

• Deflux (Dextranomer/Hyaluronic Acid): Most widely used. Non-immunogenic, biocompatible.
• Historical agents (no longer used): Teflon (migration concerns), collagen (high resorption)

Advantages:

• Minimally invasive: Outpatient/day-case procedure
• Short recovery: No incision, minimal pain, rapid return to normal activity
• Low morbidity: Very low complication rate

Success Rates:

• Grade I-II: 70-85% resolution after single injection
• Grade III: 60-70% resolution
• Grade IV-V: 30-50% resolution (lower success; often requires repeat injection or open surgery)
• Bilateral VUR: Can treat both sides in same session

Repeat Injections:

• If first injection fails to resolve VUR (check VCUG at 3-6 months), repeat injection can be performed
• Success rate after second injection: Additional 20-30% resolution
• Cumulative success after 2-3 injections approaches that of open surgery in low-moderate grade VUR

Complications (rare):

• Ureteric obstruction: Overly large mound can obstruct ureter (less than 1-2% risk; usually resolves spontaneously or with endoscopic incision of mound)
• De novo contralateral reflux: Rare (less than 5%)
• Infection: UTI, pyelonephritis (prophylactic antibiotics given perioperatively)
• Migration of material: Deflux generally stays in place; historical issue with Teflon

Follow-Up:

• USS at 1-2 weeks post-procedure (check for hydronephrosis suggesting obstruction)
• VCUG at 3-6 months (confirm VUR resolution)
• Continue prophylaxis until VCUG confirms resolution

Current Role:

• Increasingly used as first-line surgical intervention for Grade III-IV VUR (less invasive than reimplantation)
• If fails, can proceed to open reimplantation
• Cost-effectiveness debated (multiple injections vs. single open surgery)

Exam Detail: Viva Scenario: "Describe the technique and success rates of endoscopic treatment for VUR."

Model Answer:

"Endoscopic treatment of VUR involves cystoscopic injection of a bulking agent, most commonly dextranomer/hyaluronic acid copolymer known as Deflux, into the submucosal space just beneath the ureteric orifice. This is called the STING technique - Subureteric Transurethral Injection. The bulking agent creates a small mound or 'nipple' that narrows the ureteric orifice and effectively lengthens the intramural tunnel, restoring the anti-reflux valve mechanism.

It's performed as a day-case procedure under general anesthesia with minimal morbidity. Success rates vary by VUR grade: approximately 70-85% for Grade I-II, 60-70% for Grade III, and 30-50% for Grade IV-V. If the first injection doesn't resolve the reflux - assessed on VCUG at 3-6 months - a repeat injection can be performed, with cumulative success rates approaching those of open surgery for lower grades.

Advantages include minimal invasiveness, rapid recovery, and low complication rate. The main complications are ureteric obstruction from an overly large mound (less than 2%, usually transient) and the possibility that it may not work, particularly in high-grade VUR, necessitating eventual open reimplantation. It has become the preferred first-line surgical option for many surgeons managing Grade III-IV VUR, reserving open surgery for failures or Grade V cases."

2. Open Ureteric Reimplantation

Principle:

• Surgical recreation of a competent vesicoureteral junction with an adequate length intramural tunnel (tunnel-to-diameter ratio of 5:1)
• Gold standard for definitive VUR correction

Surgical Techniques:

Multiple techniques exist; choice depends on surgeon preference, VUR laterality, and anatomy.

Operative Details:

• Approach: Open (lower abdominal Pfannenstiel or midline incision) or laparoscopic/robotic
• Ureter mobilized: Detached from bladder (taking care to preserve blood supply and avoid injury)
• New tunnel created: Submucosal dissection to create adequate length tunnel
• Ureter reimplanted: Secured to bladder mucosa, ensuring no kinking or obstruction
• Stent: Ureteric stent sometimes placed (controversial; some surgeons routinely stent, others only if concerned about edema/obstruction)
• Catheter: Urethral catheter for bladder drainage (12-48 hours postop)
• Hospital stay: Typically 2-4 days

Success Rate: Greater than 95% for resolution of VUR (all grades) in experienced hands.

Complications:

• Ureteric obstruction (2-5%): Due to kinking, edema, or stricture at reimplantation site. May require stenting or revision surgery.
• Persistent or recurrent VUR (less than 5%): Technical failure; may require redo surgery.
• De novo contralateral reflux (5-10% in unilateral cases): Unclear mechanism (possibly altered bladder dynamics, unmasking of subclinical contralateral VUR).
• Bladder dysfunction: Transient urgency, frequency, bladder spasms (usually resolve within weeks).
• Ureteral injury: Devascularization (rare with careful technique).
• Infection: Wound infection, UTI.
• Hematuria: Common in early postoperative period; resolves spontaneously.

Postoperative Follow-Up:

• USS at 1-2 weeks (check for hydronephrosis suggesting obstruction)
• VCUG at 3-6 months (confirm VUR resolution)
• Continue antibiotic prophylaxis until VCUG confirms resolution
• Long-term monitoring: Even after successful surgery, children with previous VUR and scarring require lifelong BP and renal function monitoring

Laparoscopic/Robotic Reimplantation:

• Gaining popularity due to cosmetic advantages (small incisions), potentially reduced pain, and shorter hospital stay
• Requires advanced skills and significant learning curve
• Success rates comparable to open surgery (95%+) in experienced centers
• Particularly attractive for bilateral VUR (avoids larger open incision)
• Higher cost (robotic equipment) and longer operative time (currently) are limitations

Clinical Pearl: Cohen vs. Politano-Leadbetter Decision:

The choice between techniques often comes down to bilaterality and future ureteric access:

• Cohen cross-trigonal is excellent for bilateral VUR (both ureters crossed in single operation, very high success rate). However, the crossed position makes future retrograde ureteric catheterization very difficult (ureters enter from opposite sides). This is relevant if the child is at risk for future urological issues (e.g., stone disease, need for stenting).
• Politano-Leadbetter or Lich-Gregoir maintain ipsilateral position, preserving the ability to catheterize ureters retrogradely in the future. Preferred if future ureteric access may be needed.

For most children with isolated VUR and no other urological issues, Cohen is most commonly used due to its versatility for bilateral cases and excellent success rate.

3. Comparison: Endoscopic Injection vs. Open Reimplantation

Decision-Making:

• Grade I-III VUR: Endoscopic injection often first-line surgical choice (less invasive, good success)
• Grade IV-V VUR: Open reimplantation often preferred (higher success, definitive)
• Failed endoscopic injection: Proceed to open reimplantation
• Bilateral high-grade VUR: Open reimplantation (e.g., Cohen technique) may be preferred for definitive, simultaneous correction
• Patient/family preference: Some families prefer single definitive surgery; others prefer trial of less invasive approach first

---

10. Complications and Long-Term Outcomes

Acute Complications

Recurrent Pyelonephritis

• Most common complication
• Risk factors: Higher VUR grade, non-compliance with prophylaxis, bladder-bowel dysfunction
• Each episode carries risk of additional renal damage
• Cumulative effect: Multiple episodes → Progressive scarring

Urosepsis

• Rare but serious: Pyelonephritis progressing to bacteremia/sepsis
• More common in infants, immunocompromised, or obstructed systems
• Requires hospitalization, IV antibiotics

Chronic Complications: Reflux Nephropathy

Definition: Permanent renal scarring (detected on DMSA scan) resulting from VUR-associated pyelonephritis, leading to functional impairment.

Prevalence:

• Occurs in 10-15% of children with VUR (varies by grade and UTI history)
• Higher risk: High-grade VUR, recurrent UTI, delayed diagnosis, young age at first UTI

Pathological Features:

• Cortical scarring: Fibrosis, tubular atrophy, glomerulosclerosis
• Polar distribution: Classic pattern (upper and lower poles affected more than mid-kidney)
• Reduced nephron mass: Loss of functional renal tissue

Clinical Consequences:

1. Hypertension [20]

   • Prevalence: 10-20% of children/adults with reflux nephropathy develop hypertension
   • Mechanism: Ischemic renal parenchyma → Increased renin secretion → Activation of RAAS
   • Age of onset: Can occur in childhood or emerge in adulthood
   • Management: ACE inhibitors or ARBs (reduce proteinuria, protect remaining nephrons, control BP)
   • Monitoring: Lifelong BP checks (at least annually)

2. Proteinuria

   • Prevalence: 10-20% of patients with reflux nephropathy
   • Mechanism: Glomerular damage from focal segmental glomerulosclerosis (FSGS) secondary to hyperfiltration in remaining nephrons
   • Significance: Marker of progressive renal damage; accelerates CKD progression
   • Management: ACE inhibitors/ARBs (reduce proteinuria), dietary protein restriction (controversial)

3. Chronic Kidney Disease (CKD) [4]

   • Prevalence: VUR/reflux nephropathy accounts for 5-15% of children with CKD and 3-5% of adults requiring dialysis/transplantation
   • Risk factors: Bilateral high-grade VUR, recurrent UTI, extensive scarring (greater than 50% of renal parenchyma affected)
   • Natural history: Progressive decline in eGFR over years to decades
   • Monitoring: Annual U&E, eGFR, urinalysis; more frequent if CKD Stage 3 or higher
   • Management:
     • Control hypertension (target BP less than 90th centile for age)
     • Reduce proteinuria (ACE-I/ARB)
     • Treat metabolic complications (anemia, bone disease, growth failure)
     • Dietary management (protein restriction, phosphate control)
     • Prepare for renal replacement therapy (dialysis, transplantation) if Stage 5 CKD

4. Pregnancy-Related Complications (Females with Reflux Nephropathy)

   • Risks: Increased risk of UTI/pyelonephritis during pregnancy, pre-eclampsia (if hypertensive), worsening proteinuria, preterm delivery
   • Management: Preconception counseling, close monitoring during pregnancy (BP, renal function, urine cultures), low-threshold for UTI treatment

5. End-Stage Renal Disease (ESRD)

   • Rare outcome, but VUR is a recognized cause of pediatric ESRD
   • Bilateral severe reflux nephropathy with progressive CKD → Dialysis and kidney transplantation

Prognosis:

• Unilateral scarring: Generally good prognosis; contralateral kidney compensates. Monitor BP.
• Bilateral scarring: Higher risk of hypertension and CKD. Requires lifelong nephrology follow-up.
• Extensive scarring (greater than 50% involvement): High risk of progressive CKD to ESRD.

Exam Detail: Viva Question: "What are the long-term complications of reflux nephropathy?"

Model Answer:

"Reflux nephropathy refers to permanent renal scarring resulting from VUR-associated pyelonephritis. The long-term complications are significant and include:

1. Hypertension: Occurs in 10-20% of patients with reflux nephropathy. The mechanism is activation of the renin-angiotensin system by ischemic scarred renal tissue. Hypertension can develop in childhood or adulthood and requires lifelong monitoring. It's managed with ACE inhibitors or ARBs.

2. Proteinuria: Develops in 10-20% due to secondary focal segmental glomerulosclerosis from hyperfiltration injury in the remaining functional nephrons. Proteinuria is both a marker of damage and an accelerator of further CKD progression.

3. Chronic Kidney Disease: VUR and reflux nephropathy account for 5-15% of pediatric CKD and 3-5% of adults reaching end-stage renal disease. The risk is highest with bilateral high-grade VUR, extensive scarring, and recurrent UTI. Progression is gradual, over years to decades.

4. Pregnancy complications: Women with reflux nephropathy face increased risks during pregnancy, including pyelonephritis, pre-eclampsia (especially if hypertensive), and preterm delivery. Preconception counseling and close monitoring are essential.

The key message is that even after VUR has resolved - spontaneously or surgically - children with established scarring require lifelong follow-up with annual blood pressure checks, urinalysis for proteinuria, and renal function monitoring. Early detection and management of hypertension and proteinuria with ACE inhibitors or ARBs can slow CKD progression and reduce cardiovascular risk."

Outcomes and Prognosis by VUR Grade

---

11. Guidelines and Evidence

Key Clinical Guidelines

Landmark Trials and Studies

1. RIVUR Trial (NEJM 2014) [7]

   • Impact: Challenged routine use of antibiotic prophylaxis by showing UTI reduction but no scarring benefit
   • Clinical Implication: Shifted practice toward individualized prophylaxis decisions

2. PRIVENT Trial (Lancet 2009) [8]

   • Findings: No clear benefit of prophylaxis in mixed population of VUR and recurrent UTI
   • Limitation: Included non-VUR patients; results less applicable to isolated VUR

3. Swedish Reflux Trial (J Urol 2010) [9]

   • Design: RCT of surveillance vs. prophylaxis vs. endoscopic injection in Grade III-IV VUR
   • Findings: Prophylaxis reduced febrile UTI vs. surveillance. Endoscopic injection reduced VUR grade but similar UTI rates.
   • Implication: Supports endoscopic injection as alternative to long-term prophylaxis

4. International Reflux Study in Children (IRSC) (1981-1987) [15]

   • Historic RCT: Medical (prophylaxis) vs. surgical management
   • Findings: Similar long-term outcomes (renal growth, scarring, BP) in both groups for Grade III-IV VUR
   • Implication: Challenged surgical-first approach; established medical management as acceptable

5. Birmingham Reflux Study (Arch Dis Child 1987)

   • Long-term follow-up of children with VUR into adulthood
   • Findings: 10-20% developed hypertension; CKD risk correlated with extent of scarring
   • Implication: Justifies lifelong follow-up for patients with reflux nephropathy

---

12. Patient and Layperson Explanation

What is Vesicoureteral Reflux?

Vesicoureteral reflux (VUR) is a condition where urine flows backwards from the bladder up into the tubes (ureters) that connect to the kidneys. Normally, urine only travels one way – from the kidneys, down the ureters to the bladder, and out when your child urinates. In VUR, there's a problem with the "valve" where the ureter enters the bladder, so urine can flow back up toward the kidneys.

Why Does It Happen?

In most cases, VUR is something your child is born with. The valve at the junction between the ureter and bladder didn't develop quite right, so it doesn't close properly. This is called "primary" VUR. It often runs in families – if one child has VUR, siblings have about a 30-50% chance of having it too.

Less commonly, VUR can develop because of high pressure in the bladder from another problem, like a blockage. This is called "secondary" VUR.

Why Does It Matter?

The main concern with VUR is that if your child gets a bladder infection (urinary tract infection or UTI), the germs can travel backwards up to the kidneys along with the refluxing urine. This can cause a kidney infection (pyelonephritis), which is more serious than a bladder infection.

Repeated kidney infections, especially in young children (under 3 years old), can sometimes cause scarring in the kidneys. Over time, this scarring can lead to:

• High blood pressure (even in childhood or as an adult)
• Kidney problems (reduced kidney function)
• Rarely, serious kidney disease requiring dialysis or transplant (only in severe cases)

The good news is that not all children with VUR get kidney damage. Many children with VUR never have a UTI, and without infection, the reflux usually doesn't cause harm. The key is preventing infections and catching them early if they do occur.

How Is It Diagnosed?

VUR is usually discovered in one of two ways:

1. After a UTI: If your child has had a kidney infection (especially as a baby or toddler), the doctor may recommend tests to check for VUR.
2. Before birth: Sometimes VUR is suspected if an ultrasound during pregnancy shows swollen kidneys (hydronephrosis), and tests after the baby is born confirm it.

The main test to diagnose VUR is called an MCUG (Micturating Cystourethrogram). This involves:

• Inserting a small, temporary tube (catheter) into the bladder through the urethra
• Filling the bladder with a special liquid that shows up on X-rays
• Taking X-ray pictures while your child urinates to see if the liquid flows backwards into the ureters/kidneys

This test tells us if VUR is present and how severe it is (graded from I to V, with I being mild and V being severe).

Other tests may include:

• Ultrasound scan of the kidneys (to check size and structure)
• DMSA scan (a special scan to check for kidney scarring)

How Is It Treated?

Treatment depends on how severe the VUR is and whether your child has had infections:

For Mild to Moderate VUR (Grades I-III):

"Watchful Waiting" with Preventive Measures

• Low-dose antibiotic at bedtime (antibiotic prophylaxis): This is a very small dose of antibiotic taken once a day to help prevent bladder infections. It's like a shield. However, not all doctors recommend this for all children – it's a decision we make together based on your child's specific situation.
• Treat constipation: Constipation can make VUR worse and increase the risk of UTI. We'll make sure your child's bowel habits are healthy.
• Encourage regular toilet breaks: Holding urine for too long increases UTI risk.
• Regular check-ups: Ultrasound scans, blood pressure checks, and sometimes repeat tests to see if the VUR is getting better.

Why wait? Most children with mild to moderate VUR outgrow it naturally as the bladder grows. The valve improves on its own by about age 5-7 years in 70-90% of cases.

For Severe VUR (Grades IV-V) or If Antibiotics Don't Work:

Surgical Treatment

If the VUR is severe or your child keeps getting infections despite antibiotics, we might recommend fixing it with a procedure:

1. Endoscopic Injection ("Deflux" procedure):

   • A minimally invasive procedure done through a small camera (cystoscope) placed in the bladder
   • A gel-like substance is injected under the opening of the ureter to create a little mound that helps the valve close better
   • Day-case surgery (your child goes home the same day or next day)
   • Success rate: About 70-80% for moderate VUR; may need a repeat injection

2. Open Surgery (Ureteric Reimplantation):

   • An operation to move the ureter and create a longer tunnel through the bladder wall, which improves the valve
   • Requires a small incision in the tummy and a few days in hospital
   • Very effective (success rate greater than 95%)
   • Usually reserved for severe VUR or if the injection doesn't work

What Can We Do at Home?

• Watch for signs of UTI: Fever without obvious cold/flu symptoms, tummy pain, pain when urinating, smelly or cloudy urine, irritability (in babies). If you notice these, see your doctor promptly.
• Give antibiotics as prescribed (if your child is on prophylaxis): It's important to give the medicine every day, even when your child seems well.
• Encourage fluids: Drinking plenty of water helps flush out the bladder.
• Healthy toilet habits: Regular toilet breaks, no rushing, front-to-back wiping (for girls).
• Treat constipation: High-fiber diet, plenty of fluids, laxatives if needed.

What Happens Long-Term?

For most children, the outlook is very good:

• Low-grade VUR usually resolves on its own by school age
• With good infection prevention and early treatment of any UTIs, most children do not develop kidney scarring
• Children who do have some scarring on scans but feel well still usually have normal kidney function and lead entirely normal lives

However, if your child has had kidney scarring, they will need:

• Regular check-ups into adulthood: Blood pressure checks and kidney function tests (blood and urine tests) at least once a year
• Healthy lifestyle: Staying hydrated, maintaining a healthy weight, not smoking (when older)
• Awareness: Knowing that if they develop high blood pressure or kidney problems later, it may be related to the childhood VUR, and it's important to tell their doctors

For girls: If your daughter has had VUR and kidney scarring, she should inform her doctor if she becomes pregnant in the future, as there's a slightly higher risk of UTI and high blood pressure during pregnancy. With good monitoring, pregnancies are usually safe and successful.

Questions Parents Often Ask

Q: Did I do something wrong during pregnancy to cause this?
A: No. VUR is a developmental variation that happens as the baby grows in the womb. It's not caused by anything you did or didn't do.

Q: Will my other children have it too?
A: There's about a 30-50% chance that siblings of a child with VUR also have it, especially if they're under 2 years old. We can discuss whether screening (ultrasound or other tests) is recommended for brothers and sisters.

Q: Can my child swim, play sports, and live a normal life?
A: Absolutely! VUR doesn't stop children from being active and doing all normal activities.

Q: Will my child need antibiotics forever?
A: No. Antibiotic prophylaxis is usually only needed for a few years while the VUR is present and the risk of infection is higher. Once the VUR resolves (either naturally or with treatment), the antibiotics can be stopped. We'll recheck with scans to know when it's safe to stop.

Q: What if my child gets a UTI despite the antibiotics?
A: "Breakthrough" UTIs can happen. If it's a one-off, we'll treat it and continue as before. If it happens repeatedly, it's a sign that antibiotics alone aren't enough, and we'd discuss other options like the procedures mentioned above.

---

13. References

Primary Sources and Key Evidence

1. Smellie JM, Prescod NP, Shaw PJ, Riccabona M, Turi S. Childhood reflux and urinary infection: a follow-up of 10-41 years in 226 adults. Pediatr Nephrol. 1998;12(9):727-736. PMID: 9874316. DOI: 10.1007/s004670050534

2. Shaikh N, Ewing AL, Bhatnagar S, Hoberman A. Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics. 2010;126(6):1084-1091. PMID: 21059720. DOI: 10.1542/peds.2010-0685

3. Fanos V, Cataldi L. Antibiotics or surgery for vesicoureteral reflux in children. Lancet. 2004;364(9446):1720-1722. PMID: 15530633. DOI: 10.1016/S0140-6736(04)17359-4

4. Wennerstrom M, Hansson S, Jodal U, Stokland E. Primary and acquired renal scarring in boys and girls with urinary tract infection. J Pediatr. 2000;136(1):30-34. PMID: 10636970. DOI: 10.1016/s0022-3476(00)90045-5

5. Piepsz A, Blaufox MD, Gordon I, et al. Consensus on renal cortical scintigraphy in children with urinary tract infection. Semin Nucl Med. 1999;29(2):160-174. PMID: 10321827. DOI: 10.1016/s0001-2998(99)80005-3

6. Craig JC, Simpson JM, Williams GJ, et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. N Engl J Med. 2009;361(18):1748-1759. PMID: 19864673. DOI: 10.1056/NEJMoa0902295

7. RIVUR Trial Investigators. Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med. 2014;370(25):2367-2376. PMID: 24795142. DOI: 10.1056/NEJMoa1401811

8. Garin EH, Olavarria F, Garcia Nieto V, Valenciano B, Campos A, Young L. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics. 2006;117(3):626-632. PMID: 16510640. DOI: 10.1542/peds.2005-1362

9. Holmdahl G, Brandstrom P, Lackgren G, et al. The Swedish reflux trial in children: II. Vesicoureteral reflux outcome. J Urol. 2010;184(1):280-285. PMID: 20488494. DOI: 10.1016/j.juro.2010.03.060

10. Noe HN. The long-term results of prospective sibling reflux screening. J Urol. 1992;148(5 Pt 2):1739-1742. PMID: 1433594. DOI: 10.1016/s0022-5347(17)37013-0

11. Phan V, Traubici J, Hershenfield B, Stephens D, Rosenblum ND, Geary DF. Vesicoureteral reflux in infants with isolated antenatal hydronephrosis. Pediatr Nephrol. 2003;18(12):1224-1228. PMID: 14577024. DOI: 10.1007/s00467-003-1290-z

12. Skoog SJ, Peters CA, Arant BS Jr, et al. Pediatric vesicoureteral reflux guidelines panel summary report: Clinical practice guidelines for screening siblings of children with vesicoureteral reflux and neonates/infants with prenatal hydronephrosis. J Urol. 2010;184(3):1145-1151. PMID: 20650483. DOI: 10.1016/j.juro.2010.05.066

13. Wan J, Skoog SJ, Hulbert WC, et al. Section on Urology response to new Guidelines for the diagnosis and management of UTI. Pediatrics. 2012;129(4):e1051-e1053. PMID: 22430449. DOI: 10.1542/peds.2011-3615

14. Mackie GG, Stephens FD. Duplex kidneys: a correlation of renal dysplasia with position of the ureteral orifice. J Urol. 1975;114(2):274-280. PMID: 1152296. DOI: 10.1016/s0022-5347(17)67007-5

15. Weiss R, Duckett J, Spitzer A. Results of a randomized clinical trial of medical versus surgical management of infants and children with grades III and IV primary vesicoureteral reflux (United States). The International Reflux Study in Children. J Urol. 1992;148(5 Pt 2):1667-1673. PMID: 1433576. DOI: 10.1016/s0022-5347(17)36990-0

16. Ransley PG, Risdon RA. Reflux nephropathy: effects of antimicrobial therapy on the evolution of the early pyelonephritic scar. Kidney Int. 1981;20(6):733-742. PMID: 7334749. DOI: 10.1038/ki.1981.204

17. Lebowitz RL, Olbing H, Parkkulainen KV, Smellie JM, Tamminen-Mobius TE. International system of radiographic grading of vesicoureteric reflux. International Reflux Study in Children. Pediatr Radiol. 1985;15(2):105-109. PMID: 3975102. DOI: 10.1007/BF02388714

18. National Institute for Health and Care Excellence (NICE). Urinary tract infection in under 16 s: diagnosis and management. Clinical guideline [CG54]. Published August 2007. Updated October 2018. Available at: https://www.nice.org.uk/guidance/cg54

19. Koff SA, Wagner TT, Jayanthi VR. The relationship among dysfunctional elimination syndromes, primary vesicoureteral reflux and urinary tract infections in children. J Urol. 1998;160(3 Pt 2):1019-1022. PMID: 9719268. DOI: 10.1097/00005392-199809020-00011

20. Bailey RR. The relationship of vesico-ureteric reflux to urinary tract infection and chronic pyelonephritis-reflux nephropathy. Clin Nephrol. 1973;1(3):132-141. PMID: 4783715.

---

14. Examination Focus

High-Yield Topics for MRCPCH / Paediatric Exams

Written Exam (MCQ/SBA) High-Yield Points

1. VUR Grading: Memorize the International Reflux Grading System (I-V). Commonly tested: "Which grade shows mild-moderate dilation with blunting of fornices?" (Answer: Grade III)

2. Investigation Pathway (NICE CG54): Know age-based triggers for USS, DMSA, and MCUG. Key fact: MCUG indicated for all infants less than 6 months with UTI.

3. DMSA vs. Ultrasound: DMSA is gold standard for renal scarring (85-95% sensitivity). Ultrasound has poor sensitivity (30-40%).

4. RIVUR Trial: Antibiotic prophylaxis reduces recurrent UTI by 50% but does NOT significantly reduce renal scarring. Common viva question.

5. Resolution Rates: Grade I-II: 80-85% resolve by age 5. Grade III: 50-60%. Grade IV: 30-40%. Grade V: Less than 10%.

6. Complications: Reflux nephropathy → Hypertension (10-20%), CKD (5-15% of pediatric CKD), proteinuria.

7. Surgical Success Rates: Endoscopic injection (Deflux): 70-85% for Grade I-III. Open reimplantation: Greater than 95% all grades.

8. Familial Risk: Siblings of VUR patients have 30-50% risk. Screening recommended for siblings less than 2 years.

Clinical Exam (OSCE/Long Case) Scenarios

Station 1: History Taking - Child with Recurrent UTI

Scenario: 18-month-old girl, third episode of febrile UTI in past 6 months. Mother concerned about repeated infections.

Key Points to Cover:

• Detailed UTI history: Fever, irritability, vomiting, dysuria (if verbal), urine odor, confirmed by culture
• Timing and treatment of previous episodes
• Bladder and bowel habits: Constipation? Withholding? Frequency of voiding? Wetting?
• Antenatal history: Any hydronephrosis detected on prenatal scans?
• Family history: Any siblings or parents with VUR, recurrent UTI, kidney problems?
• Developmental history (normal milestones?)
• Growth (failure to thrive?)
• Red flags: Blood in urine, poor urinary stream (PUV?), neurological symptoms (neuropathic bladder?)

Diagnostic Approach to Discuss:

• "Given this is her third UTI at 18 months, NICE guidelines recommend renal ultrasound and DMSA scan to check for structural abnormalities and scarring. MCUG may be considered if ultrasound is abnormal or there's a family history of VUR."

---

Station 2: Examination - Cardiovascular Focus (BP Measurement in Child with VUR)

Scenario: Examine the cardiovascular system in this 6-year-old with a history of VUR and renal scarring.

Key Steps:

• Introduce, consent, wash hands
• Blood Pressure Measurement (ESSENTIAL):
  • Use age-appropriate cuff (bladder width 40% of arm circumference)
  • Measure in right arm, child relaxed, arm supported at heart level
  • Compare to centile charts for age, sex, and height
  • State: "I would measure BP as hypertension is a complication of reflux nephropathy."
• Cardiovascular examination as usual (pulses, heart sounds, murmurs, signs of heart failure)
• Additional relevant checks:
  • Abdominal examination (palpable kidneys? Scars from previous surgery?)
  • Check for edema (nephrotic syndrome if severe renal impairment - rare)

Discussion Point: "Reflux nephropathy can cause hypertension in 10-20% of patients due to activation of the renin-angiotensin system by scarred renal tissue. Early detection and treatment with ACE inhibitors is important to prevent cardiovascular complications and slow CKD progression."

---

Station 3: Data Interpretation - MCUG Images

Scenario: You are shown MCUG images. Grade the VUR and discuss management.

Systematic Approach:

1. Confirm reflux: Is contrast visible in the ureter/renal pelvis during voiding phase? (If no → No VUR)
2. Assess extent:
   • Ureter only, not reaching pelvis → Grade I
   • Ureter + pelvis/calyces, no dilation → Grade II
   • Mild-moderate dilation, minimal fornix blunting → Grade III
   • Moderate dilation, clubbed calyces, tortuous ureter → Grade IV
   • Gross dilation, loss of papillary impressions → Grade V
3. Bilateral or unilateral?
4. Other findings: Bladder trabeculation? Dilated posterior urethra (PUV in males)?

Management Discussion:

• Grade I-II: Conservative. Discuss prophylaxis vs. surveillance.
• Grade III: Conservative first-line with prophylaxis. Monitor for resolution.
• Grade IV-V: Discuss surgical options (endoscopic injection vs. open reimplantation).

---

Viva Voce Questions and Model Answers

Question 1: "What is vesicoureteral reflux and how does it cause renal damage?"

Model Answer: "Vesicoureteral reflux is the retrograde flow of urine from the bladder into the ureter and kidney, caused by an incompetent vesicoureteral junction. The normal VUJ functions as a one-way valve due to the oblique entry of the ureter into the bladder and a submucosal tunnel that is compressed during voiding. In VUR, this tunnel is congenitally short, resulting in valve incompetence.

VUR itself - sterile reflux - rarely causes significant renal damage. The critical mechanism of injury is the combination of VUR and infection. When a child with VUR develops a UTI, infected urine refluxes into the renal pelvis and, in susceptible areas like the renal poles where compound papillae exist, can reflux directly into collecting ducts - called intrarenal reflux. This delivers bacteria to the renal parenchyma, causing acute pyelonephritis with intense inflammation. Repeated episodes lead to scarring, fibrosis, and loss of functional renal tissue - termed reflux nephropathy.

Infants and young children under 3 years are particularly vulnerable due to the morphology of their renal papillae and possibly immature immune responses. This is why early detection and treatment of UTI is critical in this age group."

---

Question 2: "Discuss the role of antibiotic prophylaxis in VUR management."

Model Answer: "Antibiotic prophylaxis - typically low-dose trimethoprim or nitrofurantoin given once daily at night - has traditionally been used to prevent recurrent UTI in children with VUR, with the goal of preventing pyelonephritis and subsequent renal scarring.

However, the evidence for prophylaxis has become more nuanced following the RIVUR trial, published in the New England Journal of Medicine in 2014. This large RCT of over 600 children with Grade I-IV VUR showed that prophylaxis reduced the rate of recurrent febrile UTI by approximately 50%, but importantly, did not significantly reduce the development of new renal scars on DMSA scanning.

This has shifted practice toward a more individualized approach:

• Prophylaxis may still be considered for higher-grade VUR (III-V) where UTI risk is substantial, in very young infants, or in children with bladder-bowel dysfunction.
• For lower-grade VUR (I-II), many clinicians now use surveillance without prophylaxis, relying on parental education for prompt recognition and treatment of UTI.
• The decision involves shared decision-making with families, weighing the benefit of UTI reduction against concerns about antibiotic resistance, side effects, and the burden of daily medication.

Other important trials include the PRIVENT trial and the Swedish Reflux Trial, with somewhat variable results. Cochrane meta-analyses suggest modest UTI reduction but no clear scarring benefit. The key message is that prophylaxis is not universally mandatory, and should be tailored to the individual child's risk profile and family preferences."

---

Question 3: "What are the surgical options for VUR, and how do you decide between them?"

Model Answer: "The two main surgical options are endoscopic injection and open or laparoscopic ureteric reimplantation.

Endoscopic injection involves cystoscopic injection of a bulking agent, typically dextranomer/hyaluronic acid copolymer called Deflux, into the submucosal space beneath the ureteric orifice. This creates a mound that improves valve competence. It's minimally invasive, performed as a day-case procedure, with success rates of 70-85% for Grade I-III VUR and 30-50% for Grade IV-V. It may require repeat injection if the first attempt doesn't resolve the reflux.

Open ureteric reimplantation involves surgically recreating the vesicoureteral junction with an adequate-length intramural tunnel. Techniques include Cohen cross-trigonal reimplantation (commonly used for bilateral VUR), Politano-Leadbetter, or Lich-Gregoir extravesical approaches. Success rates exceed 95% for all grades. It's more invasive, requiring a 2-4 day hospital stay and 1-2 week recovery, but provides definitive correction.

Decision-making depends on several factors:

• For Grade I-III VUR with breakthrough infections despite prophylaxis, endoscopic injection is often first-line due to its minimally invasive nature.
• For Grade IV-V VUR, open reimplantation may be preferred for higher success rates and definitive correction.
• If endoscopic injection fails, we proceed to open reimplantation.
• Family preference also plays a role - some families prefer a single definitive surgery, while others prefer trying the less invasive option first.

Increasingly, laparoscopic or robotic-assisted reimplantation is being used, offering similar success rates to open surgery with smaller incisions and potentially faster recovery, though it requires specialized expertise."

---

Question 4: "What long-term follow-up is required for a child with VUR and renal scarring?"

Model Answer: "Children with VUR and established renal scarring require lifelong follow-up due to the risk of reflux nephropathy complications, even if the VUR itself has resolved.

Childhood and adolescence:

• Blood pressure monitoring: At least annually, using age-appropriate centile charts. Hypertension develops in 10-20% of patients with reflux nephropathy and can occur even in childhood.
• Urinalysis: Annual screening for proteinuria using spot urine protein:creatinine ratio. Proteinuria is a marker of glomerular damage and progressive CKD.
• Renal function: Annual blood tests for urea, creatinine, and eGFR to monitor for declining kidney function.
• Renal imaging: Periodic ultrasound to assess renal growth and size.

Transition to adult care:

• Continued nephrology follow-up into adulthood, as CKD can progress gradually over decades.
• If hypertension or proteinuria develop, treatment with ACE inhibitors or ARBs is initiated to slow progression and reduce cardiovascular risk.

Special considerations for females:

• Preconception counseling: Women with reflux nephropathy should inform their obstetrician before pregnancy, as there's increased risk of UTI, pyelonephritis, pre-eclampsia (if hypertensive), and preterm delivery. Close monitoring during pregnancy is essential.

The key message is that even after VUR has resolved - whether spontaneously or surgically - the kidney damage (scarring) is permanent and carries long-term risks. Early detection and management of hypertension and proteinuria can significantly improve outcomes and reduce the risk of progressive CKD and cardiovascular disease."

---

Summary: Key Points for Exams

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and be made in consultation with appropriate specialists. Always refer to current local and national guidelines.